Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Tyra Biosciences, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences, Inc. (“Tyra” or “the Company”) (NASDAQ: TYRA). Investors who purchased Tyra securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Tyra has violated federal securities laws.
Tyra Investigation Details
On September 9, 2026, Tyra issued a press release “announc[ing] initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC).” While the Company said that the data indicated a favorable safety profile, 14% and 9% of participants in the 60 mg once-daily (“QD”) and 50 mg QD dose cohorts experienced Grade 3 treatment-emergent adverse events. Following this news, Tyra’s stock price dropped $4.72 per share, or 17.66%, to close at $22.01 on September 9, 2026.
What’s Next for Tyra Investors?
If you are aware of any facts relating to this investigation or purchased Tyra securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
TYRA — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”